ALVR实时信号 | 通过Getagraph.com最大化利润

购买 107565 min ago

@ $0.677

发出时间: 15 Feb 2024 @ 04:54

回报率: 16.65%

上一信号: Feb 14 - 02:31

上一信号: 出售

回报率: 0.83 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:39):

Stats
今日成交量	1 020.00
平均成交量	651 298
市值	90.79M
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $-0.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.430
ATR14	$0.00200 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Hagen Brett R	Sell	473	Common Stock
2024-04-22	Hagen Brett R	Sell	480	Common Stock
2024-04-19	Miller Edward	Sell	626	Common Stock
2024-04-22	Miller Edward	Sell	757	Common Stock
2024-04-19	Brainard Diana	Sell	9 601	Common Stock

INSIDER POWER
83.67
Last 98 transactions
Buy: 5 809 216 \| Sell: 427 568

音量相关性

長: 0.22 (neutral)

短: 0.84 (strong)

Signal:(46.586) Same movement expected

AlloVir, Inc. 相关性

10 最正相关
BCLI	0.953
CVAC	0.952
CRNC	0.951
RSLS	0.949
PYPD	0.948
LYT	0.947
IKT	0.944
TNYA	0.944
RANI	0.943
SONN	0.942

10 最负相关
EBSB	-0.952
HERA	-0.95
ISEE	-0.949
FXCO	-0.946
MTRX	-0.944
GXII	-0.943
FTPA	-0.943
NOVV	-0.943
TBSA	-0.942
HERAU	-0.94

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AlloVir, Inc. 相关性 - 货币/商品

0.10
( neutral )

-0.24
( neutral )

0.00
( neutral )

0.39
( neutral )

AlloVir, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-398 000 (0.00 %)
EPS:	$-1.830

FY	2023
营收:	$0
毛利润:	$-398 000 (0.00 %)
EPS:	$-1.830

FY	2022
营收:	$0
毛利润:	$-2.57M (0.00 %)
EPS:	$-2.20

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-6.39

Financial Reports:

No articles found.

AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

实时更新： AlloVir, Inc. [ALVR]

Upcoming Earnings Alert